Watch MANE. Know when insiders buy.
One email the day a filing lands. Free.
Work order
63
WATCH · insiders 25, shorts 100
Insiders, 90 days
−$80.4M
net selling · 0 buys, 2 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $4.1BP/E —DIV YIELD —FCF YIELD -1.74%REV TTM —NET INCOME −$70MNET CASH —52W 37.03 – 129.74SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$29.6M | −$23.5M | — | -0.58 | −$14.5M | $21K | −$14.5M | Aug 11 |
| Q1 2026 · Mar 31 | — | — | — | −$29.9M | −$27.2M | — | -1.32 | −$21.2M | $0 | −$21.2M | Aug 11 |
| Q2 2025 · Jun 30 | — | — | — | −$16.1M | −$15.6M | — | -24.19 | −$15.6M | $0 | −$15.6M | Aug 11 |
| Q1 2025 · Mar 31 | — | — | — | −$12.9M | −$12.4M | — | -19.79 | −$13.3M | $19K | −$13.3M | Aug 11 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$72.3M | −$70M | — | -111.91 | −$71.6M | $24K | −$71.6M | — | — |
| FY2024 · to Dec 31 | — | — | −$26.8M | −$26.5M | — | -37.05 | −$23.7M | $0 | −$23.7M | — | — |
Every number comes from Veradermics, Inc's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.